How Wider Losses At Stoke Therapeutics (STOK) Have Changed Its Investment Story

Simply Wall St.01:25

Stoke Therapeutics reported third quarter 2026 sales of US$11.26 million compared with US$10.63 million a year earlier, alongside a wider quarterly net loss of US$73.64 million and basic and diluted ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682825307?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-09 01:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682825307","market":"sg","top_or_hot":-1,"title":"How Wider Losses At Stoke Therapeutics (STOK) Have Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>Stoke Therapeutics reported third quarter 2026 sales of US$11.26 million compared with US$10.63 million a year earlier, alongside a wider quarterly net loss of US$73.64 million and basic and diluted ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-wider-losses-at-stoke-therapeutics-stok-have-changed-its\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Wider Losses At Stoke Therapeutics (STOK) Have Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Wider Losses At Stoke Therapeutics (STOK) Have Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-09 01:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-wider-losses-at-stoke-therapeutics-stok-have-changed-its><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stoke Therapeutics reported third quarter 2026 sales of US$11.26 million compared with US$10.63 million a year earlier, alongside a wider quarterly net loss of US$73.64 million and basic and diluted ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-wider-losses-at-stoke-therapeutics-stok-have-changed-its\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STOK","symbol_name":"Stoke Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-wider-losses-at-stoke-therapeutics-stok-have-changed-its","article_id":"2682825307","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stok/stoke-therapeutics/news/how-wider-losses-at-stoke-therapeutics-stok-have-changed-its","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682825307","pubTimestamp":1794158744,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 8, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"STOK":"Stoke Therapeutics, Inc.","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","PMDE":"PGIM S&P 500 Max Buffer ETF - December","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","BK4139":"生物科技"},"translate_title":"Stoke Therapeutics (STOK) 的更广泛损失如何改变其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":1.5,"PMDE":0.67,"FEBU":0.67,"DECU":0.67},"content_text":"Stoke Therapeutics reported third quarter 2026 sales of US$11.26 million compared with US$10.63 million a year earlier, alongside a wider quarterly net loss of US$73.64 million and basic and diluted loss per share of US$1.08 from continuing operations. For the first nine months of 2026, the business moved from prior year profit to a net loss of US$185.27 million as sales were US$26.81 million compared with US$183.02 million, reflecting the impact of development spending and reliance on future pipeline progress. This analysis considers how Stoke Therapeutics' investment narrative is influenced by the sharp swing to a year-to-date net loss.  Spot opportunities across rare disease and biotech by scanning our hand picked 19 high quality undiscovered gems that share Stoke Therapeutics' high-risk, high-upside profile.\nAdvertisementStoke Therapeutics Investment Narrative Recap For Stoke Therapeutics, the central belief is that its antisense platform can produce disease modifying treatments in Dravet syndrome and Autosomal Dominant Optic Atrophy that justify years of heavy investment. The latest quarterly update reinforces how expensive that bet is. Sales were modest, and the nine month results swung from profit to a sizable loss, keeping the firm firmly in cash burn mode. The key near term swing factor still rests on late stage data and regulatory decisions around zorevunersen in Dravet syndrome. The recent numbers do not change that core catalyst, but the widened loss raises the stakes. Extended timelines or extra data requirements would matter more now because they stretch funding needs and lengthen the path to any meaningful product revenue. The most relevant update in this earnings release is the confirmation of how sharply Stoke Therapeutics moved from a nine month profit a year ago to a US$185.27 million loss on much lower reported sales. That pattern underlines how dependent the story is on collaboration revenue timing and on future product contribution rather than on an already diversified top line. For shareholders, that shift ties directly back to the EMPEROR Phase III program and eventual payer discussions. Success in that program could help support future Dravet syndrome commercialization. By contrast, any request from regulators for longer follow up or additional trials would likely keep operating losses elevated. Until there is clarity on those data, the business remains a high research spend vehicle with limited current revenue support. Stoke Therapeutics' current analyst story points to forecast revenue of US$177.8 million and projected earnings of US$33.6 million by 2029, built on an assumed 77.0% yearly revenue growth rate and an earnings swing of about US$203.4 million from earnings today of a US$169.8 million loss. Discover why Stoke Therapeutics' fair value points to a 70% potential upside to its current price, which could narrow quickly. NasdaqGS:STOK 1-Year Stock Price Chart Exploring Other Perspectives One alternate view on Stoke Therapeutics focuses primarily on slower payer uptake rather than trial risk. The most cautious analysts had pencilled in only US$23.1 million of revenue and US$4.4 million of earnings by 2029, with a very high implied P/E multiple, even before this earnings miss. That more pessimistic path shows how far opinions can differ, so treat this result as new information that could reshape both perspectives and consider several angles before deciding where you stand. Explore 3 other Stoke Therapeutics fair value estimates, including one that suggests it could be worth just $35.00! Form Your Own Verdict Don't just follow the ticker; dig into the data and build a conviction that's truly your own.  A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Stoke Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Stoke Therapeutics? Stoke Therapeutics shows how concentrated and binary a single biotech position can feel. If you want to spread that risk and compare this story with other listed businesses, the Simply Wall St Screener can help you quickly scan for stocks that better match your own comfort level on volatility, balance sheet strength, and income needs.  If resilience and downside protection are your priority, you can filter for companies flagged as lower risk using our 31 resilient stocks with low risk scores. Investors hunting for quality at a reasonable price can review a curated pool of attractively priced opportunities with the 38 high quality undervalued stocks. If balance sheet strength matters most, you can focus on businesses with cleaner finances using the list of solid balance sheet and fundamentals (25 results).  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682825307","isCrawlerRequest":true}